Nifty
Sensex
:
:
13133.90
44632.65
20.15 (0.15%)
14.61 (0.03%)

Pharmaceuticals & Drugs - API

Rating :
72/99

BSE: 541540 | NSE: SOLARA

1199.85
03-Dec-2020
  • Open
  • High
  • Low
  • Previous Close
  •  1198.90
  •  1211.00
  •  1175.00
  •  1191.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  118064
  •  1412.58
  •  1255.00
  •  364.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,276.85
  • 27.05
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,926.86
  • 0.17%
  • 2.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.24%
  • 7.32%
  • 13.89%
  • FII
  • DII
  • Others
  • 12.2%
  • 4.20%
  • 18.15%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 33.11

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 32.83

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 570.62

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 20
Sep 19
Var%
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Net Sales
397.56
351.13
13.22%
348.42
330.17
5.53%
296.77
385.31
-22.98%
343.68
356.23
-3.52%
Expenses
299.94
283.11
5.94%
264.62
266.49
-0.70%
246.69
320.66
-23.07%
266.02
294.26
-9.60%
EBITDA
97.62
68.02
43.52%
83.80
63.68
31.60%
50.08
64.65
-22.54%
77.66
61.97
25.32%
EBIDTM
24.55%
19.37%
24.05%
19.29%
14.01%
14.01%
22.60%
17.40%
Other Income
6.12
4.95
23.64%
4.58
4.36
5.05%
12.13
6.63
82.96%
6.08
3.88
56.70%
Interest
19.37
20.29
-4.53%
19.83
18.65
6.33%
20.38
21.72
-6.17%
18.57
22.54
-17.61%
Depreciation
27.60
23.50
17.45%
26.23
22.89
14.59%
23.93
23.40
2.26%
23.84
21.21
12.40%
PBT
56.77
29.18
94.55%
42.32
26.50
59.70%
17.90
26.16
-31.57%
41.33
22.10
87.01%
Tax
0.08
0.30
-73.33%
0.05
0.00
0
0.09
-0.04
-
0.00
0.00
0
PAT
56.69
28.88
96.30%
42.27
26.50
59.51%
17.81
26.20
-32.02%
41.33
22.10
87.01%
PATM
14.26%
8.22%
12.13%
8.03%
7.11%
7.11%
12.03%
6.20%
EPS
15.84
8.07
96.28%
11.81
7.40
59.59%
4.97
7.32
-32.10%
11.54
6.17
87.03%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 20
Mar 19
Mar 18
Net Sales
1,386.43
1,321.75
1,408.58
560.41
Net Sales Growth
-2.56%
-6.16%
151.35%
 
Cost Of Goods Sold
5,116.14
598.87
724.03
293.38
Gross Profit
-3,729.71
722.88
684.55
267.03
GP Margin
-269.02%
54.69%
48.60%
47.65%
Total Expenditure
1,077.27
1,076.32
1,210.16
501.05
Power & Fuel Cost
-
77.68
79.35
31.41
% Of Sales
-
5.88%
5.63%
5.60%
Employee Cost
-
204.13
187.82
71.51
% Of Sales
-
15.44%
13.33%
12.76%
Manufacturing Exp.
-
94.74
101.85
48.02
% Of Sales
-
7.17%
7.23%
8.57%
General & Admin Exp.
-
47.70
35.50
15.22
% Of Sales
-
3.61%
2.52%
2.72%
Selling & Distn. Exp.
-
24.70
31.33
17.84
% Of Sales
-
1.87%
2.22%
3.18%
Miscellaneous Exp.
-
28.50
50.28
23.66
% Of Sales
-
2.16%
3.57%
4.22%
EBITDA
309.16
245.43
198.42
59.36
EBITDA Margin
22.30%
18.57%
14.09%
10.59%
Other Income
28.91
27.52
12.38
2.47
Interest
78.15
77.89
82.48
25.17
Depreciation
101.60
80.15
70.57
36.46
PBT
158.32
114.91
57.75
0.20
Tax
0.22
0.39
-1.66
-0.14
Tax Rate
0.14%
0.34%
-2.87%
-70.00%
PAT
158.10
114.61
59.51
0.38
PAT before Minority Interest
158.12
114.52
59.41
0.34
Minority Interest
0.02
0.09
0.10
0.04
PAT Margin
11.40%
8.67%
4.22%
0.07%
PAT Growth
52.49%
92.59%
15,560.53%
 
EPS
44.16
32.01
16.62
0.11

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Shareholder's Funds
1,085.94
955.87
763.98
Share Capital
26.85
25.77
24.67
Total Reserves
958.36
823.71
739.30
Non-Current Liabilities
333.31
344.23
315.06
Secured Loans
232.71
224.97
242.86
Unsecured Loans
0.00
0.00
0.00
Long Term Provisions
32.62
28.79
23.58
Current Liabilities
729.89
655.50
737.95
Trade Payables
216.12
244.38
312.87
Other Current Liabilities
157.28
192.24
90.08
Short Term Borrowings
353.79
214.47
330.21
Short Term Provisions
2.70
4.41
4.78
Total Liabilities
2,153.43
1,959.98
1,821.47
Net Block
1,368.46
1,188.56
1,063.41
Gross Block
1,581.04
1,309.21
1,099.87
Accumulated Depreciation
212.58
120.65
36.46
Non Current Assets
1,481.44
1,311.88
1,213.66
Capital Work in Progress
40.47
40.37
71.48
Non Current Investment
28.80
29.65
23.33
Long Term Loans & Adv.
40.83
36.23
46.40
Other Non Current Assets
2.88
17.07
9.03
Current Assets
671.99
648.10
607.81
Current Investments
0.00
0.00
0.00
Inventories
279.73
213.94
187.66
Sundry Debtors
226.53
288.80
262.52
Cash & Bank
56.78
76.47
47.01
Other Current Assets
108.95
49.13
75.48
Short Term Loans & Adv.
69.08
19.76
35.14
Net Current Assets
-57.90
-7.40
-130.14
Total Assets
2,153.43
1,959.98
1,821.47

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Cash From Operating Activity
244.22
166.33
49.22
PBT
114.91
57.75
0.20
Adjustment
170.10
148.26
62.76
Changes in Working Capital
-16.45
-25.29
-10.84
Cash after chg. in Working capital
268.56
180.72
52.11
Interest Paid
0.00
0.00
0.00
Tax Paid
-24.34
-14.39
-2.89
Other Direct Exp. Paid
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
Cash From Investing Activity
-358.81
-115.69
-85.47
Net Fixed Assets
-272.61
-178.25
Net Investments
0.58
-6.62
Others
-86.78
69.18
Cash from Financing Activity
94.91
-23.39
67.74
Net Cash Inflow / Outflow
-19.68
27.25
31.49
Opening Cash & Equivalents
75.72
45.95
0.00
Closing Cash & Equivalent
56.04
75.72
45.95

Financial Ratios

Standalone /

Consolidated
Description
Mar 20
Mar 19
Mar 18
Book Value (Rs.)
366.93
329.64
309.63
ROA
5.57%
3.14%
0.02%
ROE
12.48%
7.36%
0.04%
ROCE
11.73%
9.70%
1.82%
Fixed Asset Turnover
0.91
1.17
0.51
Receivable days
71.15
71.43
170.98
Inventory Days
68.16
52.03
122.23
Payable days
76.71
85.40
228.56
Cash Conversion Cycle
62.61
38.07
64.65
Total Debt/Equity
0.72
0.63
0.83
Interest Cover
2.48
1.70
1.01

Annual Reports:

News Update:


  • CRISIL upgrades ratings of Solara Active Pharma Sciences
    25th Sep 2020, 16:03 PM

    CRISIL has upgraded Solara Active Pharma Sciences’ long term rating to A-/Stable

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.